Trigger finger Trigger finger, Trigger digit, Snapping finger, Flexor Tendonitis
Conditions
Interventions
We inject within the tendon sheath in two ways.
(1) Triamcinolone acetonide 0.1 ml (4 mg) + 1% mepivacaine 0.2 ml ( local anesthetic group) and
(2) Triamcinolone acetonide 0.1 ml (4 mg) + 0.2 ml of sa
injection
Sponsors
Fukumoto Keizo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Trigger finger, Men and women over 20 years old, No history of injections in the affected finger
Exclusion criteria
Exclusion criteria: Diabetic patients, patients with a history of trauma to the affected finger, patients with numbness in the affected finger, patients with symptoms in more than one finger on the affected side at the time of visit, and patients allergic to local anesthetics or steroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary efficancy outcime: difference in pain VAS before and 1 month after injection primary safety outcome:Frequency of numbness and adverse events (flexor tendon rupture, tendon sheath rupture, skin atrophy, skin leukoplakia, nerve damage, infection) | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) pain VAS at the time of injection, (2) pain VAS at 10 minutes after injection, and (3) Quinnell classification. | — |
Contacts
Public ContactHideaki Bo
Fuji City General Hospital
Outcome results
None listed